611 W. Union Street
Benson, AZ 85602
(520) 586-0800

Health Choice Integrated Care crisis Line
1-877-756-4090

NurseWise 24-Hour Crisis Line
1-866-495-6735

NAZCARE Warm Line
1-888-404-5530



SEABHS
611 W. Union Street
Benson, AZ 85602
(520) 586-0800

NurseWise 24-Hr Crisis Line
1-866-495-6735

NAZCARE Warm Line
1-888-404-5530


powered by centersite dot net

Getting Started
Here are some forms to get started. These can be printed and brought with you so that you can pre-fill out some known info ahead of time. More...


Medical Disorders
Resources
Basic InformationLookupsLatest News
Popular Heartburn Meds Don't Raise Alzheimer's Risk: StudyHealth Tip: Manage Dry MouthHealth Tip: Exercise to Manage Knee PainSound Progress Made Toward Global Containment of PoliovirusGene Sequencing May Reveal Risks for Rare DiseasesHigher Fish Intake Appears to Reduce RA SymptomsReview Spotlights Optimal Care of T2DM + OsteoporosisAcne-Related Depression, Anxiety Not Tied to Oxidative StressStudy Challenges Touted Link Between Eczema and Heart DiseaseImmunizations for High Flyin' TravelersCarpal Tunnel Up With Increased Electronic Device UseGuided Approach to Exercise May Help Chronic Fatigue PatientsFamily History Questionnaire Ups Genetic Counseling for CRCBlood Test Can Detect GLUT1 Deficiency SyndromeWallpaper May Breed Toxins: StudyFish Eaters Report Less Rheumatoid Arthritis PainGuided Exercise May Help Chronic Fatigue Patients: Study2006 to 2013 Saw Increase in ER Use for Herpes ZosterNearly 60 Percent With Conjunctivitis Fill Antibiotic RxTissue Testing Can Spot Zika at Birth: CDCGuidelines Address Peri-Op Care in Rheumatic DiseaseZika-Bearing Mosquitoes More Widespread in U.S. Than ExpectedMarital Status Among Factors Tied to Gout Rx AdherenceMany Chronic Illnesses Linked to Suicide RiskVaccine Curbs High Cholesterol in MiceStudy Hints at Link Between Some Statins, Parkinson's RiskHydrotherapy Plus Conventional Drugs Beneficial in RAChronic Lyme Disease Treatments Tied to Serious Adverse EffectsOlder Age Needn't Be a Barrier to Herniated Disc SurgeryNon-Opioid Drug More Effective for Migraines: StudyHealth Tip: Managing Arthritis FatigueCertain Criteria May Be Better Than Others in RA Assessment20 Percent of Hospital Patients Have Side Effects From Abx RxRecreational Activity-Linked Facial Fractures Up in SeniorsUnusual Measles Outbreak Described in Ontario in Early 2015Seniors Get Good Results From Herniated Disc Surgery'Good' Donor Bacteria Can Last Long Term in Stool Transplant PatientsNovel Retinal Lesion Seen in Some Ebola SurvivorsHealth Tip: Recognizing Summer Allergy SymptomsAre You at Risk for Metabolic Syndrome?Antiplatelet Bleeding Risk Higher Than Expected for Older PatientsVideo Call May Be as Good as Doctor Visit for HeadacheCould Prefab Blood Vessels Revolutionize Root Canals?A Sufferer's Guide to Easin' Sneezin' SeasonHospitals Get Good News About Fighting Staph InfectionsCases of Legionnaires' Disease Reported in NYC, Las VegasOlive Oil, Ibuprofen May Have Synergistic EffectsObesity Prevalence Has Doubled in More Than 70 CountriesSeveral New Medications in the Pipeline to Prevent MigraineReview: Depression Screening As Inpatient Important, Feasible
Questions and AnswersLinksBook Reviews
Related Topics

Cancer
Men's Health
Women's Health

Lower Risk of Gastrointestinal Bleeding for Apixaban


HealthDay News
Updated: Apr 10th 2017

new article illustration

MONDAY, April 10, 2017 (HealthDay News) -- For patients receiving direct oral anticoagulant (DOAC) agents for non-valvular atrial fibrillation, apixaban is associated with a lower risk of gastrointestinal (GI) bleeding than rivaroxaban or dabigatran, according to a study published in the April issue of Gastroenterology.

Neena S. Abraham, M.D., from the Mayo Clinic in Scottsdale, Ariz., and colleagues conducted a retrospective study using administrative claims data of privately insured individuals and Medicare Advantage enrollees. Three propensity-matched cohorts of patients with non-valvular atrial fibrillation with incident exposure to dabigatran, rivaroxaban, or apixaban were created. Data were compared on rivaroxaban versus dabigatran for 31,574 patients; for apixaban versus dabigatran for 13,084 patients; and for apixaban versus rivaroxaban for 13,130 patients.

The researchers found that GI bleeding occurred more often in patients given rivaroxaban versus dabigatran (hazard ratio, 1.2). The risk of GI bleeding was lower for apixaban versus dabigatran or rivaroxaban (hazard ratios, 0.39 and 0.33, respectively). For apixaban and rivaroxaban, the median times to gastrointestinal bleeding were <90 days, while for dabigatran, the median time was <120 days.

"In a population-based study of patients receiving DOAC agents, we found apixaban had the most favorable GI safety profile and rivaroxaban the least favorable profile " the authors write.

Abstract
Full Text
Editorial